Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman diseaseGaurav Goyal, Ronald S. Go, Karen L. Rech et al.|Haematologica|2019Cited by 215
The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman DiseaseGaurav Goyal, Ronald S. Go, Caroline Davidge‐Pitts et al.|Mayo Clinic Proceedings|2019Cited by 190
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patientsErika Morsia, Naseema Gangat, Aref Al‐Kali et al.|American Journal of Hematology|2020Cited by 136
Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed <i>FLT3</i> Mutated AMLSelina M. Luger, Mark R. Litzow, Ellin Berman et al.|Blood|2024Cited by 7
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohortMithun Vinod Shah, Devendra Hiwase, David T Yeung et al.|Blood Cancer Journal|2025Cited by 6